Tryptamine Therapeutics (ASX:TYP) completed the dosing component of its phase 1b trial, administering the intravenous-infused psilocin TRP-8803 in three obese individuals, according to a Friday filing with the Australian bourse.
Psilocin is used in psychedelic-assisted psychotherapy and has potential neuroplastic benefits, which may help in providing structural and functional changes in the brain.
The trial aims to compare the pharmacokinetic profile of psilocybin in obese individuals with non-obese individuals, the filing said.
Results will be used to advance the program into a phase 2 trial investigating the use of TRP-8803 in weight-related indications such as binge-eating disorder, the filing added.
Company shares rose nearly 5% in recent Friday trade.
Price (AUD): $0.05, Change: $+0.002, Percent Change: +4.65%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。